Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan + G-CSF Mobilization in MM
NCT00008268Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2000
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety of melphalan with filgrastim at 1 month and Efficacy of mobilization at 1 month. Started Aug 2000; status: completed.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00008268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008268.